This company is no longer active
Frequency Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Frequency Therapeutics has a total shareholder equity of $36.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $46.3M and $9.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$41.72m |
| Equity | US$36.74m |
| Total liabilities | US$9.61m |
| Total assets | US$46.35m |
Recent financial health updates
Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Frequency...Recent updates
Financial Position Analysis
Short Term Liabilities: FREQ's short term assets ($42.5M) exceed its short term liabilities ($9.6M).
Long Term Liabilities: FREQ has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: FREQ is debt free.
Reducing Debt: FREQ had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FREQ has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: FREQ has less than a year of cash runway if free cash flow continues to reduce at historical rates of 30.3% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/05 04:34 |
| End of Day Share Price | 2023/11/03 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Frequency Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Daniil Gataulin | Chardan Capital Markets, LLC |